Customized Chromosomal Microarrays for Neurodevelopmental Disorders.

Researchers created a specialized genetic test focusing on over 6,000 genes linked to brain development. They tested 39 children with autism, intellectual disability, or developmental delays. The test found genetic changes that could explain symptoms in about 1 in 3 children (31%). The study also identified important genes that act like 'control centers' in brain development and found that brain support cells (called glial cells) play a bigger role in autism than previously understood.

This study developed a customized chromosomal microarray (CMA) targeting 6,026 neurodevelopment-related genes to improve genetic diagnosis in autism spectrum disorder and other neurodevelopmental conditions. Testing 39 patients with unexplained developmental delays, intellectual disability, or ASD, researchers identified pathogenic or likely pathogenic copy number variants (CNVs) in 31% of cases. Advanced network analysis revealed key candidate genes functioning as central 'hubs' and regulatory 'bottlenecks' in brain development. The approach highlighted glial cells and immune pathways as important in neurodevelopmental conditions, identifying several novel CNV regions with high pathogenic potential and providing a framework for prioritizing new candidate genes for future research.

The customized microarray approach shows promise for improving genetic diagnosis in autism and neurodevelopmental conditions. The 31% diagnostic yield suggests clinical utility. Identification of glial involvement supports research into neuroinflammation and immune pathways as therapeutic targets. Novel candidate genes identified warrant further functional studies.

Small sample size of 39 patients limits generalizability. Network analysis findings require functional validation. The study focuses on CNVs only, not other genetic variations. Clinical significance interpretation challenges remain for some variants identified.

Neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD), are genetically complex and often linked to structural genomic variations such as copy number variants (CNVs). Current diagnostic strategies face challenges in interpreting the clinical significance of such variants. We developed a customized, gene-oriented chromosomal microarray (CMA) targeting 6026 genes relevant to neurodevelopment, aiming to improve diagnostic yield and candidate gene prioritization. A total of 39 patients with unexplained developmental delay, intellectual disability, and/or ASD were analyzed using this custom platform.

Systems biology approaches were employed for downstream interpretation, including protein-protein interaction networks, centrality measures, and tissue-specific functional module analysis. Pathogenic or likely pathogenic CNVs were identified in 31% of cases (9/29). Network analyses revealed candidate genes with key topological properties, including central "hubs" (e.g.,,,) and regulatory "bottlenecks" (e.g.,,,). Tissue- and cell-type-specific network modeling demonstrated widespread gene involvement in both prenatal and postnatal developmental modules, with glial and astrocytic networks showing notable enrichment.

Several novel CNV regions with high pathogenic potential were identified and linked to neurodevelopmental phenotypes in individual patient cases. Customized CMA offers enhanced detection of clinically relevant CNVs and provides a framework for prioritizing novel candidate genes based on biological network integration. This approach improves diagnostic accuracy in NDDs and identifies new targets for future functional and translational studies, highlighting the importance of glial involvement and immune-related pathways in neurodevelopmental pathology.